Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs P 276 (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Piramal Phytocare
- 26 Jul 2012 Planned end date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 11 Apr 2012 Status changed from active, no longer recruiting to discontinued as reported by Clinical Trials Registry - India.
- 10 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.